Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 296 Products   1145 Diseases   296 Products   3757 Trials   200588 News 


«12...7891011121314151617...22902291»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Retrospective data, Journal, Checkpoint inhibition:  CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma. (Pubmed Central) -  Feb 24, 2025   
    This comprehensive study enriched the understanding of listeriosis cases and diversity of clinical isolates, meanwhile, indicated the spread characteristics of CC1, CC8, and CC87 in China based on phylogeny analysis, providing fundamental data for developing targeting food safety interventions to prevent listeriosis. The CRAFITY score is a valuable predictor of survival and treatment outcomes in patients receiving lenvatinib and PD-1 inhibitors.
  • ||||||||||  Winrevair (sotatercept-csrk) / BMS, Merck (MSD), seralutinib (GB002) / Gossamer Bio
    Journal, PARP Biomarker:  New therapies in pulmonary arterial hypertension: Recent insights. (Pubmed Central) -  Feb 24, 2025   
    Subsequent sections describe treatments that target epigenetic regulators, e.g. poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and direct BRD4 antagonists, tyrosine kinase inhibitors (Seralutinib), and therapies aimed at inflammation, such as IL-6 inhibitors, CD-20 inhibitors, and monoclonal antibodies that prevent macrophage migration...This review includes both preclinical and clinical trial data that support efficacy, safety and the future potential of such therapies. Collectively, these therapeutic approaches can be valuable in treating PAH by targeting multiple aspects of its pathogenesis, potentially resulting in improved clinical outcomes for patients affected by this debilitating, life-limiting condition.
  • ||||||||||  Review, Journal:  Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine. (Pubmed Central) -  Feb 24, 2025   
    The final assessment result scores from highest to lowest were rimegepant (84.5 points), erenumab (75.78 points), galcanezumab (74.02 points), fremanezumab (73.93 points), atogepant (72.64 points), eptinezumab (71.69 points), ubrogepant (70.37 points), zavegepant (56.44 points). Rimegepant, erenumab, fremanezumab, atogepant, galcanezumab, eptinezumab, ubrogepant can be entered into the medication list of medical institutions as strongly recommended drugs.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Inflammatory Bowel Disease in a Patient Returning from Colombia: Association with Dipeptidyl Peptidase 4 Inhibitor? (Pubmed Central) -  Feb 24, 2025   
    Ultimately, the cessation of sitagliptin therapy resulted in rapid symptom resolution and normalization of eosinophilia, as well as endoscopic improvement...This case underscores the importance of considering IBD secondary to DPP-4 inhibitor use in the evaluation of patients with recent-onset IBD. Further research is needed to elucidate the pathophysiological mechanisms underlying the relationship between DPP-4 inhibitors and IBD.
  • ||||||||||  Orgaran (danaparoid) / Merck (MSD)
    Journal:  "Keep HIT in Mind and Take Care". Multiple Tips From a Single Patient. (Pubmed Central) -  Feb 24, 2025   
    Discontinuation of warfarin could lead to catastrophic consequences if an unrecognized HIT is ongoing, and an alternative anticoagulant is not started. Bivalirudin and danaparoid were used after the diagnosis of HIT, adapting anticoagulant therapy to the needs of recent surgery.
  • ||||||||||  dizocilpine (MK801) / Merck (MSD)
    Preclinical, Journal:  17?-estradiol status alters NMDAR function and antipsychotic-like activity in female rats. (Pubmed Central) -  Feb 24, 2025   
    Collectively, these studies established a relationship between E2 deprivation and NMDAR function that is in part GluN2A-dependent, supporting the notion that E2 deprivation increases susceptibility to NMDAR hypofunction. This highlights the need to examine age/hormone-specific factors when considering antipsychotic response and designing novel pharmacotherapies.
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Journal:  Role of the NuRD complex and altered proteostasis in cancer cell quiescence. (Pubmed Central) -  Feb 24, 2025   
    We also find that both primary qOvCa and vorinostat-induced qOvCa demonstrate altered proteostasis, including increased proteasome activity and autophagy, and combination therapy of HDACi and proteasome inhibitors or autophagy inhibitors demonstrated profound synergistic death of OvCa cells. Finally, we overlapped RNA-Seq signatures from quiescent ovarian cancer cells with genes essential for quiescence in yeast to identify a "quiescent cell core signature." This core quiescent cell signature appeared to be conserved across multiple cancer types, suggesting new therapeutic targets.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Pembrolizumab-induced thyroid storm. (Pubmed Central) -  Feb 24, 2025   
    Thyroid storm associated with ICIs is extremely rare. We present a case of a 34-year-old woman with metastatic ovarian carcinoma who developed thyroid storm shortly after an addition of pembrolizumab.
  • ||||||||||  Remicade (infliximab) / J&J
    Journal:  Insulin sensitivity in moderately severe to acute severe ulcerative colitis. (Pubmed Central) -  Feb 24, 2025   
    During the index flare, four patients received second-line treatment with infliximab due to non-response to GC, and one patient was subsequently referred for acute subtotal colectomy...The study demonstrates that patients with moderately severe to severe UC experience significant insulin resistance, irrespective of the outcome of the flare. The reduced insulin sensitivity is likely driven by a combination of active inflammation and GC treatment, as insulin sensitivity returned to normal levels when patients achieved remission during follow-up.
  • ||||||||||  Remicade (infliximab) / J&J
    Journal:  The Gut Microbiota Affects Anti-TNF Responsiveness by Activating the NAD+ Salvage Pathway in Ulcerative Colitis. (Pubmed Central) -  Feb 24, 2025   
    Here, it is found that the transplantation of gut fecal microbiota from patients with UC alters the diversity of the gut microbiota in dextran sulfate sodium-induced colitis mice and may affect the therapeutic responsiveness of mice to infliximab...Mechanistically, F. nucleatum promotes the nicotinamide adenine dinucleotide (NAD+) salvage pathway by upregulating NAMPT expression, which subsequently leads to the activation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway and promotes the secretion of inflammatory factors, ultimately inhibiting the therapeutic response to anti-TNF drugs. These findings demonstrate that the gut microbiota can influence the response to anti-TNF therapy in patients with UC and highlight the therapeutic potential of targeting F. nucleatum and its associated pathways for preventing and treating drug resistance in UC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial primary completion date, IO biomarker:  Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia (clinicaltrials.gov) -  Feb 24, 2025   
    P2,  N=25, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment change, Trial withdrawal:  SOC-2320: A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma (clinicaltrials.gov) -  Feb 24, 2025   
    P2,  N=0, Withdrawn, 
    Trial completion date: Jan 2025 --> May 2026 N=20 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  An Integrated Virtual Screening Platform to Identify Potent Co-Assembled Nanodrugs for Cancer Treatment. (Pubmed Central) -  Feb 24, 2025   
    interactions...RNA sequencing (RNA-seq) analysis revealed that the co-assembled nanodrugs exhibited mechanisms that are distinct from those of single drugs. This study demonstrates the feasibility of utilizing a computational approach combining LBVS and DFT to identify small molecules with co-assembly capabilities, leading to innovative anticancer strategies.
  • ||||||||||  Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn) / Regeneron, Ervebo (recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoprotein of Ebola Virus Zaire) / Merck (MSD)
    New P3 trial:  EBO-PEP: EBOla Post-Exposure Prophylaxis (clinicaltrials.gov) -  Feb 24, 2025   
    P3,  N=160, Not yet recruiting, 
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Trial completion, Enrollment change:  Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study (clinicaltrials.gov) -  Feb 24, 2025   
    P2/3,  N=3, Completed, 
    This study demonstrates the feasibility of utilizing a computational approach combining LBVS and DFT to identify small molecules with co-assembly capabilities, leading to innovative anticancer strategies. Enrolling by invitation --> Completed | N=21 --> 3
  • ||||||||||  Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
    Journal:  Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine. (Pubmed Central) -  Feb 23, 2025   
    This review indicates the link between sleep disorders and MCI, DORAs are an appropriate medication category for treating insomnia, and sleep deprivation links AD and PD. In this study, subjects who had participated in one of two trials comparing two and three doses (2D, 3D), were given an additional vaccine dose (Gardasil
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Review, Journal:  Suppressing, stimulating and/or inhibiting: the evolving management of HCC patient after liver transplantation. (Pubmed Central) -  Feb 23, 2025   
    The fear of acute liver rejection and the lack of predictive factors hinder the successful clinical application of immunotherapy for post-liver transplantation HCC recurrence. This review aims to comprehensively summarize the risk of HCC-R_LT, the available evidence for the efficacy of immunotherapy in patients with HCC-R_LT, and the clinical issues regarding the innovative management of this patient population.
  • ||||||||||  atabecestat (JNJ-54861911) / J&J, verubecestat (MK-8931) / Merck (MSD), elenbecestat (E2609) / Eisai, Biogen
    Journal:  Development of novel BACE1 inhibitors with a hydroxyproline-derived N-amidinopyrrolidine scaffold. (Pubmed Central) -  Feb 22, 2025   
    Docking simulations suggested that a bulkier substituent tended to be located in the S1 and S3 pockets and that the binding mode significantly changed depending on which biphenyl group the substituent was attached to. These results show that the new scaffold would be useful for further development of small-molecule BACE1 inhibitors.